Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 153 participants.
Also called NCT06376916
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 153 participants
- Registry
-
NCT06376916
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT06376916. Randomized; double masking; primary purpose treatment. Start 2024-10-07 (actual); primary completion 2026-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
- Acronym
- ATRIUM
- Condition
- Tachycardia Atrial
- Condition
- Atrial Fibrillation
- Condition
- Atrial Flutter With Rapid Ventricular Response
- Intervention (Drug)
- Magnesium Sulfate 2 G
- Intervention (Drug)
- Magnesium Sulfate 4 G
- Intervention (Drug)
- Saline
- Lead sponsor
- Wake Forest University Health Sciences
Record details
- Record id
cardio:ct-nct06376916- Content hash
019233c5548fde329928e3b06ea322d4ad119e33cb05f3d3bdb8ad83d057666f